Tocilizumab, a monoclonal antibody that targets IL-6 and reduces SAA levels (295), has been effective in treating a small number of patients with amyloidosis involving the gastrointestinal tract (296) and kidneys associated with Familial Mediterranean Fever (297, 298), and amyloidosis associated with rheumatoid arthritis (299), but this approach could potentially also be developed for use in other chronic inflammatory conditions. Here, SAA1 is linked to familial Mediterranean fever.